Fraxiparin, a low-molecular-weight heparin, stimulates megakaryocytopoiesis in vitro and in vivo in mice.
The effect of a low-molecular-weight heparin, faxiparin (Nadroparin), on murine megakaryocytopoiesis in vitro and in vivo was studied in comparison with unfractionated heparin. The addition of fraxiparin at 1-20 IU/ml into plasma clot cultures but not serum-free agar culture significantly enhanced MK colony growth. Furthermore, fraxiparin was found to potentiate the stimulating activity of aplastic anaemia serum (AAS) but not stem cell factor (SCF), interleukin-3 (IL-3), granulocyte-macrophage colony-stimulating factor (GM-CSF) and erythropoietin (Epo), on MK colony growth in vitro, and to neutralize the inhibitory effect of platelet factor 4 (PF4) in vitro and in vivo. Fraxiparin also acted synergistically with heparin cofactor II and antithrombin III to promote megakaryocyte colony formation. Intraperitoneal administration of fraxiparin twice daily for 4 d at 0.1-25 IU/injection increased in mice the level of blood platelet counts and the number of single MKs and CFU-MK in bone marrow. These data demonstrate that fraxiparin is able to positively regulate megakaryocytopoiesis.
Shen
Z X
ZX
Institut des Vaisseaux et du Sang, Hôpital Lariboisière, Paris, France.
Basara
N
N
Xi
X D
XD
Caen
J
J
Maffrand
J P
JP
Pascal
M
M
Petitou
M
M
Lormeau
J C
JC
Han
Z C
ZC
D000818:Animals; D002455:Cell Division / Q000187:drug effects; D002478:Cells, Cultured; D008297:Male; D008533:Megakaryocytes / Q000166:cytology / Q000187:drug effects*; D051379:Mice; D008807:Mice, Inbred BALB C; D017762:Nadroparin / Q000494:pharmacology*; D013234:Stem Cells
D017762:Nadroparin